当前位置:
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Fasting conditions in clinical oncology trials and drug labelling – Authors' reply
The Lancet Oncology ( IF 41.6 ) Pub Date : 2017-09-01 , DOI: 10.1016/s1470-2045(17)30599-5 Floor J E Lubberman , David Burger , Nielka P van Erp
The Lancet Oncology ( IF 41.6 ) Pub Date : 2017-09-01 , DOI: 10.1016/s1470-2045(17)30599-5 Floor J E Lubberman , David Burger , Nielka P van Erp
The main concern addressed in our Comment is that the interpretation of modified fasted intake of an oral oncolytic drug with a narrow therapeutic index can largely affect the exposure to the drug and thereby also treatment outcome, which is currently majorly ignored.
中文翻译:
临床肿瘤学试验和药物标记中的禁食情况–作者的回复
我们的意见中涉及的主要问题是,对治疗禁忌症的口服溶瘤药的禁食改良摄入量的解释会极大地影响药物的暴露,从而也影响治疗结果,目前,这种治疗方法主要被忽略。
更新日期:2017-09-04
中文翻译:
临床肿瘤学试验和药物标记中的禁食情况–作者的回复
我们的意见中涉及的主要问题是,对治疗禁忌症的口服溶瘤药的禁食改良摄入量的解释会极大地影响药物的暴露,从而也影响治疗结果,目前,这种治疗方法主要被忽略。